A new pill for treating dementia is delivering promising "topline" results in early-stage clinical trials , according to a recent press release by its makers. The treatment, called VES001 after its developer Vesper Bio, is designed to tackle frontotemporal dementia (FTD) – the most common type of dementia in the under-60s . In a two-part preliminary safety trial at two medical centres in the Netherlands and the UK, VES001 was given to people showing no signs of FTD, including six volunteers